Wang L, et al. Calcineurin (CN) activation promotes apoptosis of glomerular podocytes both in vitro and in vivo. Mol Endocrinol 2011; 25:1376−1386. doi: 10.1210/me.2011-0029

• PubMed
Wang L, Calcineurin (CN) activation promotes apoptosis of glomerular podocytes both in vitro and in vivo. Mol Endocrinol 2011; 25:1376−1386. doi: 10.1210/me.2011-0029)| false
• Search Google Scholar
• Export Citation

Shen X, et al. Calcineurin inhibitors cyclosporin A and tacrolimus protect against podocyte injury induced by puromycin aminonucleoside in rodent models. Sci Rep 2016; 6:32087. doi: 10.1038/srep32087

• PubMed
Shen X, Calcineurin inhibitors cyclosporin A and tacrolimus protect against podocyte injury induced by puromycin aminonucleoside in rodent models. Sci Rep 2016; 6:32087. doi: 10.1038/srep32087)| false
• Search Google Scholar
• Export Citation

Li Y, et al. Pharmacokinetic disposition difference between cyclosporine and voclosporin drives their distinct efficacy and safety profiles in clinical studies. Clin Pharmacol 2020; 12:83−96. doi: 10.2147/CPAA.S255789

• PubMed
Li Y, Pharmacokinetic disposition difference between cyclosporine and voclosporin drives their distinct efficacy and safety profiles in clinical studies. Clin Pharmacol 2020; 12:83−96. doi: 10.2147/CPAA.S255789)| false
• Search Google Scholar
• Export Citation

Sanders ML, Langone AJ. Drugs in development for prophylaxis of rejection in kidney-transplant recipients. Transpl Res Risk Manag 2015; 7:59−69. doi: 10.2147/TRRM.S61446; https://www.dovepress.com/drugs-in-development-for-prophylaxis-of-rejection-in-kidney-transplant-peer-reviewed-fulltext-article-TRRM

• PubMed
Sanders ML, Langone AJ. Drugs in development for prophylaxis of rejection in kidney-transplant recipients. Transpl Res Risk Manag 2015; 7:59−69. doi: 10.2147/TRRM.S61446; https://www.dovepress.com/drugs-in-development-for-prophylaxis-of-rejection-in-kidney-transplant-peer-reviewed-fulltext-article-TRRM)| false
• Search Google Scholar
• Export Citation

Rovin BH, et al. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int 2019; 95:219−231. doi: 10.1016/j.kint.2018.08.025

• PubMed
Rovin BH, A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int 2019; 95:219−231. doi: 10.1016/j.kint.2018.08.025)| false
• Search Google Scholar
• Export Citation

Rovin BH, et al. Management of lupus nephritis (LN) with voclosporin: An update from a pooled analysis of 534 patients. American Society of Nephrology Kidney Week 2020. October 22, 2020. Abstract PO1917. https://www.asn-online.org/education/kidneyweek/2020/program-abstract.aspx?controlId=3446491

• PubMed
Rovin BH, Management of lupus nephritis (LN) with voclosporin: An update from a pooled analysis of 534 patients. American Society of Nephrology Kidney Week 2020. October 22, 2020. Abstract PO1917. https://www.asn-online.org/education/kidneyweek/2020/program-abstract.aspx?controlId=3446491)| false
• Search Google Scholar
• Export Citation

Arriens C, et al. Scientific Abstracts, Oral Presentations: Other orphan diseases. OP0277: AURORA phase 3 study demonstrates voclosporin statistical superiority over standard of care in lupus nephritis (LN). Ann Rheum Dis 2020; 79:172−173. https://ard.bmj.com/content/79/Suppl_1/172.2

• PubMed
Arriens C, Scientific Abstracts, Oral Presentations: Other orphan diseases. OP0277: AURORA phase 3 study demonstrates voclosporin statistical superiority over standard of care in lupus nephritis (LN). Ann Rheum Dis 2020; 79:172−173. https://ard.bmj.com/content/79/Suppl_1/172.2)| false
• Search Google Scholar
• Export Citation

Bensman A, Niaudet P. Non-immunologic mechanisms of calcineurin inhibitors explain its antiproteinuric effects in genetic glomerulopathies. Pediatr Nephrol 2010; 25:1197−1199. doi: 10.1007/s00467-010-1469-2

• PubMed
Bensman A, Niaudet P. Non-immunologic mechanisms of calcineurin inhibitors explain its antiproteinuric effects in genetic glomerulopathies. Pediatr Nephrol 2010; 25:1197−1199. doi: 10.1007/s00467-010-1469-2)| false
• Search Google Scholar
• Export Citation

Furie R, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 2020; 383:1117−1128. doi: 10.1056/NEJMoa2001180

• PubMed
Furie R, Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 2020; 383:1117−1128. doi: 10.1056/NEJMoa2001180)| false
• Search Google Scholar
• Export Citation